Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Microtubule-Targeted and Fusion-Directed Oncology.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EML4/EMAP-4 drug discovery, supporting both wild-type protein (microtubule-associated) and EML4-ALK fusion oncogene research.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT EML4) | EML4 Full-Length / WD40 Domain Protein – High purity (>95%), endotoxin <1EU/μg, HEK293 expressed for native folding, SEC-HPLC verified oligomeric state. | View EML4 Products |
| Antigen (Fusion) | EML4-ALK Mutant Protein – High purity (>95%), endotoxin <1EU/μg, sequence verified, covering key resistance mutations. | View EML4 Products |
| Gene Delivery | EML4 Promise-ORF / Lentivirus – Full-length ORF for stable cell lines, codon-optimized for high expression. | View EML4 Products |
| Benchmark Ab | Anti-EML4 (Recombinant Rabbit mAb) – Sequence-verified positive control for IP/Western, suitable for degradation assays. | View EML4 Products |
| Validator | EML4 siRNA Set – For knockdown verification and specificity controls. | View EML4 Products |
| Related Target 1: ALK | Primary fusion partner driving NSCLC oncogenesis; wild-type and mutant variants available. | View ALK Products |
| Related Target 2: EGFR | Parallel driver mutation pathway in lung cancer; useful for resistance mechanism studies. | View EGFR Products |
| Related Target 3: EML1 | Family homolog required for selectivity screening (WD40 domain homology). | View EML1 Products |
| Related Target 4: TUBB3 | Class III β-tubulin – Microtubule binding partner for PPI assays. | View TUBB3 Products |
| Related Target 5: MAPRE1 | EB1 – Microtubule plus-end tracking protein for functional and resistance studies. | View MAPRE1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trimerization-dependent conformation (WT EML4) | Monomeric and trimeric forms available; SEC-HPLC verified oligomeric state; theoretical MW confirmed by mass spec. |
| WD40 domain folding integrity (WT EML4) | HEK293 expression ensuring proper β-propeller folding; native glycosylation preserved. |
| Family selectivity (EML1/2/3/5) | Homolog panel proteins (EML1, EML2, EML3) strictly verified by mass spec for counter-screening. |
| Microtubule binding competition (WT EML4) | High-concentration stocks (>10 mg/ml) for crystallography and SPR; sequence verified for pull-down assays. |
| Intracellular target validation | Validated siRNA set for specificity checks; lentivirus for stable cell line construction and degradation assays. |
| Kinase inhibition selectivity (EML4-ALK) | Purified EML4-ALK mutant proteins (wild-type and G1202R, L1196M, etc.) for biochemical assays and SPR. |
| Evaluating drug resistance (EML4-ALK) | Fusion mutant variants strictly verified by mass spec and sequencing; allows mutant vs wild-type selectivity screening. |
| Lack of controls | Clinical benchmark antibodies included for standardization across both WT and fusion projects. |
| False positives | Validated siRNA and cell lines included for specificity checks; counter-screening with related targets. |
EML4 Functional Biology & Therapeutic Strategies
EML4 (Echinoderm Microtubule Associated Protein Like 4, also known as EMAP-4) serves dual roles in oncology: as a microtubule-associated protein that stabilizes the mitotic spindle, and as the N-terminal fusion partner of ALK in EML4-ALK rearranged NSCLC (3–5% of cases). Wild-type EML4 forms homotrimers through its coiled-coil domain and interacts with tubulin via its WD40 domain, making it a potential target for next-generation microtubule inhibitors. In contrast, EML4-ALK fusions are established driver oncogenes with approved TKIs (crizotinib, alectinib, lorlatinib). Current preclinical efforts aim at both disrupting native EML4 function (trimerization disruptors, allosteric EML4-tubulin blockers) and overcoming ALK inhibitor resistance via PROTACs or mutation-agnostic degraders.
Live EML4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
Wild-type EML4 (microtubule-associated): Currently in preclinical/lead optimization stage. First-generation microtubule inhibitors (taxanes, vinca alkaloids) face resistance; next-wave R&D targets allosteric EML4-tubulin interfaces and trimerization disruptors to induce mitotic catastrophe without direct tubulin binding. IND-enabling studies are anticipated by 2025–2026. EML4-ALK fusion: Dominated by approved TKIs, but acquired resistance (e.g., G1202R, L1196M, compound mutations) drives demand for fourth-generation inhibitors and degraders. PROTACs targeting EML4-ALK are entering early clinical phases. Overall, the global market for EML4-directed therapies (both arms) is projected to reach $8–12B within five years of first approval, primarily capturing taxane-resistant solid tumors and refractory NSCLC.
Competitive Modality & Indication Snapshot
| Modality | Representative Approach / Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule TKI (EML4-ALK) | Pfizer, Novartis, Roche – crizotinib, alectinib, lorlatinib | NSCLC | Selectivity assays (mutant vs wild-type EML4-ALK proteins) |
| Small Molecule PPI (WT EML4) | Allosteric EML4-tubulin interface blockers | Solid tumors (NSCLC, ovarian) | Trimerization-competent protein required (native conformation preservation) |
| Peptide-based | Coiled-coil domain disruptors | Taxane-resistant cancers | Heterotrimerization assays (high-purity monomeric baseline) |
| PROTAC / Degrader | Both WT EML4 and EML4-ALK targeted degradation | Refractory metastatic disease, resistant NSCLC | Cell-based validation (lentivirus stable lines for degradation assays); specific antibodies |
| Synthetic Lethality | Combination with mitotic stressors | High-grade serous carcinoma | siRNA validation tools for pathway analysis |
| Gene Therapy | Academic/emerging | Solid tumors | Knockdown validation (siRNA and verified antibodies) |
Molecular Differentiation & Assay Strategy
1. Trimerization selectivity (WT EML4): Ideal compounds should stabilize monomers or block trimer-tubulin interaction. Assays: AUC/SEC-HPLC, DLS. TarMart provides SEC-verified EML4 full-length protein.
2. Family selectivity (WT EML4): EML family (EML1–5) shares 60–70% WD40 homology; counter-screening with EML1/2/3 proteins (TarMart homolog panel) is essential.
3. Tubulin competition (WT EML4): Co-immunoprecipitation with anti-EML4 mAb and BLI/SPR with TUBB3. TarMart offers high-concentration stocks for chip immobilization.
4. Kinase inhibition and mutation coverage (EML4-ALK): Biochemical kinase assays using mutant EML4-ALK proteins (G1202R, L1196M, etc.) – available from TarMart.
5. Intracellular degradation (PROTAC): Western blot with TarMart anti-EML4 antibody; lentivirus-based stable cell lines for HiBiT or endogenous tagging.
6. Selectivity and off-target safety: Kinase panel screening (ALK, EGFR, MET, etc.) using TarMart recombinant proteins.